Glycogen phosphorylase: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 1: Line 1:
{{protein
{{Refimprove|date=January 2009}}
|Name=phosphorylase, glycogen; muscle (McArdle syndrome, [[glycogen storage disease type V]])
{{enzyme
| Name = Phosphorylase
| EC_number = 2.4.1.1
| CAS_number = 9035-74-9
| IUBMB_EC_number = 2/4/1/1
| GO_code = 0008184
| image = GlycogenPhosphorylaseDimer.png
| width =
| caption = The crystal structure of the rabbit muscle glycogen phosphorylase-AMP complex. AMP allosteric site (yellow), phosphorylated Ser14 (orange), glycogen binding site (blue), catalytic site (red).<ref name="urlwww.pdb.org">{{PDB|3E3N}}</ref>
}}
 
'''Glycogen phosphorylase''' is one of the [[phosphorylase]] [[enzyme]]s ({{EC number|2.4.1.1}}). Glycogen phosphorylase catalyzes the rate-limiting step in [[glycogenolysis]] in animals by releasing [[glucose-1-phosphate]] from the terminal alpha-1,4-glycosidic bond. Glycogen phosphorylase is also studied as a model protein regulated by both reversible [[phosphorylation]] and [[Allosteric regulation|allosteric]] effects.
 
==Mechanism==
 
Glycogen phosphorylase breaks up [[glycogen]] into [[glucose]] [[Protein subunit|subunits]] (see also figure below):
 
(α-1,4 glycogen chain)<sub>n</sub> + [[Phosphate|Pi]]  ⇌ (α-1,4 glycogen chain)<sub>n-1</sub> + α-D-glucose-1-phosphate.<ref name="PMID12460107">{{cite journal |vauthors=Livanova NB, Chebotareva NA, Eronina TB, Kurganov BI | title = Pyridoxal 5′_Phosphate as a Catalytic and Conformational Cofactor of Muscle Glycogen Phosphorylase b| journal = Biochemistry (Moscow) | volume = 67 | issue = 10 | pages = 1089–1998 |date=May 2002 | pmid = 12460107 | doi = 10.1023/A:1020978825802| url = | issn = }}</ref>
 
[[Glycogen]] is left with one fewer [[glucose]] [[molecule]], and the free [[glucose]] molecule is in the form of [[glucose-1-phosphate]]. In order to be used for [[metabolism]], it must be converted to [[glucose-6-phosphate]] by the enzyme [[phosphoglucomutase]].
 
Although the reaction is reversible in solution, within the cell the enzyme only works in the forward direction as shown below because the concentration of [[Phosphate|inorganic phosphate]] is much higher than that of glucose-1-phosphate.<ref name="PMID12460107"/>
 
[[File:Glycogen phosphorylase stereo.png|600px|center|Action of Glycogen Phosphorylase on Glycogen]]
 
Glycogen phosphorylase can act only on [[linear]] chains of [[glycogen]] (α1-4 glycosidic linkage). Its work will immediately come to a halt four residues away from α1-6 [[Branching (chemistry)|branch]] (which are exceedingly common in glycogen). In these situations, a [[glycogen debranching enzyme|debranching enzyme]] is necessary, which will straighten out the chain in that area. In addition, the enzyme transferase shifts a block of 3 glucosyl residues from the outer branch to the other end, and then a [[glycogen debranching enzyme|α1-6 glucosidase]] [[enzyme]] is required to break the remaining (single glucose) α1-6 residue that remains in the new linear chain. After all this is done, glycogen phosphorylase can continue. The enzyme is specific to α1-4 chains, as the molecule contains a 30-angstrom-long crevice with the same radius as the helix formed by the glycogen chain; this accommodates 4-5 glucosyl residues, but is too narrow for branches. This crevice connects the glycogen storage site to the active, catalytic site.
 
Glycogen phosphorylase has a [[pyridoxal phosphate]] (PLP, derived from [[Vitamin B6|Vitamin B<sub>6</sub>]]) at each catalytic site. Pyridoxal phosphate links with basic residues (in this case Lys680) and covalently forms a [[Schiff base]]. Once the Schiff base linkage is formed, holding the PLP molecule in the active site, the phosphate group on the PLP readily donates a proton to an inorganic phosphate molecule, allowing the inorganic phosphate to in turn be deprotonated by the oxygen forming the α-1,4 glycosidic linkage.  PLP is readily deprotonated because its negative charge is not only stabilized within the phosphate group, but also in the pyridine ring, thus the conjugate base resulting from the deprotonation of PLP is quite stable.  The protonated oxygen now represents a good [[leaving group]], and the glycogen chain is separated from the terminal glycogen in an [[SN1 reaction|S<sub>N</sub>1]] fashion, resulting in the formation of a glucose molecule with a secondary carbocation at the 1 position.  Finally, the deprotonated inorganic phosphate acts as a [[nucleophile]] and bonds with the carbocation, resulting in the formation of glucose-1-phosphate and a glycogen chain shortened by one glucose molecule.
 
There is also an alternative proposed mechanism involving a positively charged oxygen in a half-chair conformation.<ref name="PMID2182117">{{cite journal |vauthors=Palm D, Klein HW, Schinzel R, Buehner M, Helmreich, EJ | title = The role of pyridoxal 5'-phosphate in glycogen phosphorylase catalysis | journal = Biochemistry | volume = 29 | issue = 5 | pages = 1099–1107 |date=February 1990 | pmid = 2182117 | doi = 10.1021/bi00457a001| url = | issn = }}</ref>
 
[[File:GlycogenPhosphorylaseMechanism.png|800px|center|Catalytic Site Mechanism]]
 
==Structure==
 
The glycogen phosphorylase monomer is a large protein, composed of 842 amino acids with a mass of 97.434 [[kDa]] in muscle cells.  While the enzyme can exist as an inactive monomer or tetramer, it is biologically active as a [[protein dimer|dimer]] of two identical subunits.<ref name="PMID1566331">{{cite journal |vauthors=Browner MF, Fletterick RJ | title = Phosphorylase: a biological transducer | journal = Trends in Biochemical Sciences | volume = 17 | issue = 2 | pages = 66–71 |date=February 1992 | pmid = 1566331 | doi = 10.1016/0968-0004(92)90504-3| url = | issn = }}</ref>
 
[[Image:GlycogenPhosphorylaseTandRStates.png|thumb|400px|R and T States of Glycogen Phosphorylase b Tower Helices, on the left and right respectively. Note the relative positioning of the central tower helices, as well as the increased interactions between subunits in the R state. PDB3CEH, PDB3E3O]]
 
In mammals, the major [[isozyme]]s of glycogen phosphorylase are found in muscle, liver, and brain. The brain type is predominant in adult brain and embryonic tissues,  whereas the liver and muscle types are predominant in adult liver and skeletal muscle, respectively.<ref name="pmid3510670">{{cite journal |vauthors=David ES, Crerar MM | title = Quantitation of muscle glycogen phosphorylase mRNA and enzyme amounts in adult rat tissues | journal = Biochim. Biophys. Acta | volume = 880 | issue = 1 | pages = 78–90 |date=January 1986 | pmid = 3510670 | doi = 10.1016/0304-4165(86)90122-4| url = | issn = }}</ref>
 
The glycogen phosphorylase dimer has many regions of biological significance, including [[catalytic]] sites, glycogen binding sites, [[allosteric]] sites, and a reversibly phosphorylated serine residue.  First, the catalytic sites are relatively buried, 15Å from the surface of the protein and from the subunit interface.<ref name="PMID1544539">{{cite journal | author = Johnson LN | title = Glycogen phosphorylase: control by phosphorylation and allosteric effectors | journal = FASEB Journal | volume = 6 | issue = 6 | pages = 2274–82 |date=March 1992 | pmid = 1544539 | doi = | url = | issn = }}</ref> This lack of easy access of the catalytic site to the surface is significant in that it makes the protein activity highly susceptible to regulation, as small allosteric effects could greatly increase the relative access of glycogen to the site.
 
Perhaps the most important [[regulatory site]] is Ser14, the site of reversible [[phosphorylation]] very close to the subunit interface.  The structural change associated with phosphorylation, and with the conversion of phosphorylase b to phosphorylase a, is the arrangement of the originally disordered residues 10 to 22 into α helices.  This change increases phosphorylase activity up to 25% even in the absence of AMP, and enhances AMP activation further.<ref name="PMID2667896">{{cite journal |vauthors=Newgard CB, Hwang PK, Fletterick RJ | title = The family of glycogen phosphorylases: structure and function | journal = Critical Reviews Biochemistry and Molecular Biology | volume = 24 | issue = 1 | pages = 69–99 | year = 1989 | month = | pmid = 2667896 | doi = 10.3109/10409238909082552| url = | issn = }}</ref>
 
The allosteric site of [[Adenosine monophosphate|AMP]] binding on muscle isoforms of glycogen phosphorylase are close to the subunit interface just like Ser14.  Binding of AMP at this site, corresponding in a change from the T state of the enzyme to the R state, results in small changes in tertiary structure at the subunit interface leading to large changes in quaternary structure.<ref name="PMID2137445">{{cite journal |vauthors=Johnson LN, Barford D | title = Glycogen phosphorylase. The structural basis of the allosteric response and comparison with other allosteric proteins. | journal = Journal of Biological Chemistry | volume = 265 | issue = 5 | pages = 2409–2412 |date=February 1990 | pmid = 2137445 | doi = | url = | issn = }}</ref> AMP binding rotates the tower helices (residues 262-278) of the two subunits 50˚ relative to one another through greater organization and intersubunit interactions.  This rotation of the tower helices leads to a rotation of the two subunits by 10˚ relative to one another, and more importantly disorders residues 282-286 (the 280s loop) that block access to the catalytic site in the T state but do not in the R state.<ref name="PMID1544539"/>
 
The final, perhaps most curious site on the glycogen phosphorylase protein is the so-called glycogen storage site.  Residues 397-437 form this structure, which allows the protein to covalently bind to the glycogen chain a full 30 Å from the catalytic site .  This site is most likely the site at which the enzyme binds to glycogen granules before initiating cleavage of terminal glucose molecules.  In fact, 70% of dimeric phosphorylase in the cell exists as bound to glycogen granules rather than free floating.<ref name="PMID4320610">{{cite journal |vauthors=Meyer F, ((Heilmeyer LM Jr)), Haschke RH, Fischer EH | title = Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein-glycogen complex | journal = Journal of Biological Chemistry| volume = 245 | issue = 24 | pages = 6642–6648 |date=Dec 1970 | pmid = 4320610 | doi = | url = | issn = }}</ref>
 
==Clinical significance==
 
{{infobox protein
|Name=phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V)
|caption=
|caption=
|image=
|image=
Line 18: Line 70:
|LocusSupplementaryData=-q13.2
|LocusSupplementaryData=-q13.2
}}
}}
{{protein
{{infobox protein
|Name=phosphorylase, glycogen; liver (Hers disease, [[glycogen storage disease type VI]])
|Name=phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)
|caption=
|caption=
|image=
|image=
Line 37: Line 89:
|LocusSupplementaryData=-24.3
|LocusSupplementaryData=-24.3
}}
}}
{{protein
{{infobox protein
|Name=phosphorylase, glycogen; brain
|Name=phosphorylase, glycogen; brain
|caption=
|caption=
Line 56: Line 108:
|LocusSupplementaryData=-p11.1
|LocusSupplementaryData=-p11.1
}}
}}
{{SI}}


'''Glycogen phosphorylase''' is one of the [[phosphorylase]] [[enzyme]]s ({{EC number|2.4.1.1}}). It breaks up [[glycogen]] into [[glucose]] [[subunits]]. [[Glycogen]] is left with one less [[glucose]] [[molecule]], and the free [[glucose]] molecule is in the form of [[glucose-1-phosphate]]. In order to be used for [[metabolism]], it must be converted to [[glucose-6-phosphate]] by the enzyme [[phosphoglucomutase]].
The inhibition of glycogen phosphorylase has been proposed as one method for treating [[type 2 diabetes]].<ref name="PMID12769745">{{cite journal |vauthors=Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P | title = Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments | journal = Current Pharmacological Design | volume = 9 | issue = 15 | pages = 1177–89 | year = 2003 | month = | pmid = 12769745 | doi = 10.2174/1381612033454919| url = | issn = }}</ref>  Since glucose production in the liver has been shown to increase in type 2 diabetes patients,<ref name="PMID11742415">{{cite journal | author = Moller DE | title = New drug targets for type 2 diabetes and the metabolic syndrome | journal = Nature | volume = 414 | issue = 6865 | pages = 821–7 |date=Dec 2001 | pmid = 11742415 | doi = 10.1038/414821a| url = | issn = }}</ref> inhibiting the release of glucose from the liver’s glycogen’s supplies appears to be a valid approach.  The cloning of the human liver glycogen phosphorylase (HLGP) revealed a new allosteric binding site near the subunit interface that is not present in the rabbit muscle glycogen phosphorylase (RMGP) normally used in studies.  This site was not sensitive to the same inhibitors as those at the AMP allosteric site,<ref name="PMID1874749">{{cite journal |vauthors=Coats WS, Browner MF, Fletterick RJ, Newgard CB | title = An engineered liver glycogen phosphorylase with AMP allosteric activation | journal = Journal of Biological Chemistry | volume = 266 | issue = 24 | pages = 16113–9 |date=Aug 1991 | pmid = 1874749 | doi = | url = | issn = }}</ref> and most success has been had synthesizing new inhibitors that mimic the structure of glucose, since [[glucose-6-phosphate]] is a known inhibitor of HLGP and stabilizes the less active T-state.<ref name="PMID7867660">{{cite journal |vauthors=Oikonomakos NG, Kontou M, Zographos SE, Tsitoura HS, Johnson LN, Watson KA, Mitchell EP, Fleet GW, Son JC, Bichard CJ | title = The design of potential antidiabetic drugs: experimental investigation of a number of beta-D-glucose analogue inhibitors of glycogen phosphorylase | journal = European Journal of Drug Metabolism and Pharmacology | volume = 19 | issue = 3 | pages = 185–92 |date=Jul 1994 | pmid = 7867660 | doi = 10.1007/BF03188920| url = | issn = |display-authors=etal}}</ref>  These glucose derivatives have had some success in inhibiting HLGP, with predicted Ki values as low as 0.016 mM.<ref name="Hopfinger">{{cite journal |vauthors=Hopfinger AJ, Reaka A, Venkatarangan P, Duca JS, Wang S | title = Prediction of Ligand−Receptor Binding Free Energy by 4D-QSAR Analysis:  Application to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase | journal = Journal of Chemical Information and Computer Science | volume = 39 | issue =  | pages = 1141–1150 |date=Sep 1999 | pmid = |doi=10.1021/ci9900332 | url = | issn = }}</ref>


Glycogen phosphorylase can only act on [[linear]] [[Chain (sequence)|chain]]s of [[glycogen]] (a 1-4 glycosidic linkage). Its work will immediately come to a halt four residues away from a 1-6 [[Branching_%28chemistry%29|branch]] (which are exceedingly common in glycogen). In these situations, a [[debranching enzyme]] is necessary, which will straighten out the chain in that area. Additionally, an [[alpha 1-6 glucosidase]] [[enzyme]] is required to break the remaining 1-6 residue that remains in the new linear chain. After all this is done, glycogen phosphorylase can continue.
Mutations in the muscle isoform of glycogen phosphorylase (PYGM) are associated with [[glycogen storage disease type V]] (GSD IV, McArdle's Disease). More than 65 mutations in the PYGM gene that lead to McArdle disease have been identified to date.<ref name="pmid17217859">{{cite journal |vauthors=Nogales-Gadea G, Arenas J, Andreu AL | title = Molecular genetics of McArdle's disease | journal = Curr Neurol Neurosci Rep | volume = 7 | issue = 1 | pages = 84–92 |date=January 2007 | pmid = 17217859 | doi = 10.1007/s11910-007-0026-2| url =  }}</ref><ref name="pmid17915571">{{cite journal |vauthors=Andreu AL, Nogales-Gadea G, Cassandrini D, Arenas J, Bruno C | title = McArdle disease: molecular genetic update | journal = Acta Myol | volume = 26 | issue = 1 | pages = 53–7 |date=July 2007 | pmid = 17915571 | doi = | url = | issn = | pmc=2949323}}</ref> Symptoms of McArdle disease include muscle weakness, [[myalgia]], and lack of endurance, all stemming from low glucose levels in muscle tissue.<ref name="PMID4502558">{{cite journal |vauthors=Grünfeld JP, Ganeval D, Chanard J, Fardeau M, Dreyfus JC | title = Acute renal failure in McArdle's disease. Report of two cases | journal = New England Journal of Medicine | volume = 286 | issue = 23 | pages = 1237–41 |date=Jun 1972 | pmid = 4502558 | doi = 10.1056/NEJM197206082862304| url = | issn = }}</ref>


An [[insulin]] stimulated enzyme known as [[phosphoprotein phosphatase]] (PP-1) inactivates glycogen phosphorylase to prevent glycogen break up.
Mutations in the liver isoform of glycogen phosphorylase (PYGL) are associated with [[Hers' Disease]] ([[glycogen storage disease type VI]]).<ref name="pmid9529348">{{cite journal |vauthors=Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW | title = Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI | journal = Am. J. Hum. Genet. | volume = 62 | issue = 4 | pages = 785–91 |date=April 1998 | pmid = 9529348 | pmc = 1377030 | doi = 10.1086/301790| url = }}</ref><ref name="pmid9536091">{{cite journal |vauthors=Chang S, Rosenberg MJ, Morton H, Francomano CA, Biesecker LG | title = Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI | journal = Hum. Mol. Genet. | volume = 7 | issue = 5 | pages = 865–70 |date=May 1998 | pmid = 9536091 | doi = 10.1093/hmg/7.5.865| url =  }}</ref> Hers' disease is often associated with mild symptoms normally limited to [[hypoglycemia]], and is sometimes difficult to diagnose due to residual enzyme activity.<ref name="PMID12809646">{{cite journal |vauthors=Tang NL, Hui J, Young E, Worthington V, To KF, Cheung KL, Li CK, Fok TF | title = A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity| journal = Molecular Genetics and Metabolism | volume = 79 | issue = 2 | pages = 142–145 |date=Jun 2003 | pmid = 12809646 | doi = 10.1016/S1096-7192(03)00068-4| url = | issn = }}</ref>


Glycogen phosphorylase has a [[pyridoxal phosphate]] (PLP) at each catalytic site. Pyridoxal phosphate links with basic residues and covalently forms a [[Schiff Base]] which helps attack the substrate. PLP is covalently linked to the protein via the epsilon-amino group of a lysyl residue. PLP therefore stabilizes the attacking phosphate group.
The brain isoform of glycogen phosphorylase (PYGB) has been proposed as a [[biomarker]] for [[stomach cancer|gastric cancer]].<ref name="pmid11480789">{{cite journal |vauthors=Shimada S, Matsuzaki H, Marutsuka T, Shiomori K, Ogawa M | title = Gastric and intestinal phenotypes of gastric carcinoma with reference to expression of brain (fetal)-type glycogen phosphorylase | journal = J. Gastroenterol. | volume = 36 | issue = 7 | pages = 457–64 |date=July 2001 | pmid = 11480789 | doi = 10.1007/s005350170068| url = }}</ref>


==Regulation==
==Regulation==
The enzyme is regulated by both [[allosteric]] control and reversible phosphorylation, which is a kind of covalent regulation.
Glycogen phosphorylase is regulated by both [[allosteric]] control and by [[phosphorylation]].


Hormones such as [[adrenaline]] and [[glucagon]] regulate glycogen phosphorylase, using a secondary messenger amplification system. Adrenaline activates adenylate cyclase, which increases levels of cAMP. cAMP in turn activates [[protein kinase A]]. This phosphorylates [[phosphorylase kinase]], which is required for the activation of the glycogen phosphorylase. Phosphorylase kinase does this by converting glycogen phosphorylase from the inactive form of phosphorylase b to the active form of glycogen phosphorylase a. Glycogen phosphorylase is phosphorylated on its seryl 14 side chain.
Hormones such as [[epinephrine]], [[insulin]] and [[glucagon]] regulate glycogen phosphorylase using second messenger amplification systems that are linked to [[G proteins]]. Glucagon activates adenylate cyclase through a [[G protein-coupled receptor|seven transmembrane receptor]] coupled to [[Heterotrimeric G protein|G<sub>s</sub>]] which, in turn, activates [[adenylate cyclase]] to increase intracellular concentrations of cAMP. cAMP binds to and releases an active form of [[protein kinase A]] (PKA). Next, PKA phosphorylates [[phosphorylase kinase]], which, in turn, phosphorylates glycogen phosphorylase b, transforming it into the active glycogen phosphorylase a. This phosphorylation is added onto the glycogen phosphorylase b serine 14. In the liver, [[glucagon]] activates another G-protein-linked receptor that triggers a different cascade, resulting in the activation of Phospholipase C (PLC). PLC indirectly causes the release of calcium from the hepatocytes' endoplasmic reticulum into the cytosol. The increased calcium availability binds to the [[calmodulin]] subunit and activates glycogen phosphorylase kinase. Glycogen phosphorylase kinase activates glycogen phosphorylase in the same manner mentioned previously.


Calcium ions also indirectly activate glycogen phosphorylase, as they activate the phosphorylase kinase enzyme.
Glycogen phosphorylase b is not always inactive in muscle, as it can be activated allosterically by AMP. An increase in AMP concentration, which occurs during strenuous exercise, signals energy demand. AMP activates glycogen phosphorylase b by changing its conformation from a tense to a relaxed form. This relaxed form has similar enzymatic properties as the phosphorylated enzyme. An increase in ATP concentration opposes this activation by displacing AMP from the nucleotide binding site, indicating sufficient energy stores.


The inactive glycogen phosphorylase is not completely inactive, and can be activated by 5'AMP, which reflect energy demand. ATP opposes this activation, reflecting sufficient energy. This prevents the release of G1P when it is not needed to enter glycolysis.
Upon eating a meal, there is a release of [[insulin]], signaling glucose availability in the blood. Insulin indirectly activates [[Protein phosphatase 1|PP-1]] and [[phosphodiesterase]]. The PP-1 directly dephosphorylates glycogen phosphorylase a, reforming the inactive glycogen phosphorylase b. The phosphodiesterase converts cAMP to AMP. This activity removes the second messenger (generated by glucagon and epinephrine) and inhibits PKA. In this manner, PKA can no longer cause the phosphorylation cascade that ends with formation of (active) glycogen phosphorylase a. These modifications initiated by insulin end glycogenolysis in order to preserve what glycogen stores are left in the cell and trigger glycogenesis (rebuilding of glycogen).<ref>{{Cite journal|last=Alemany|first=Susana|last2=Pelech|first2=Steven|last3=Brierley|first3=Cathy H.|last4=Cohen|first4=Philip|date=1986-04-01|title=The protein phosphatases involved in cellular regulation|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1432-1033.1986.tb09554.x/abstract|journal=European Journal of Biochemistry|language=en|volume=156|issue=1|pages=101–110|doi=10.1111/j.1432-1033.1986.tb09554.x|issn=1432-1033}}</ref>


===Liver===
Phosphorylase a and phosphorylase b each exist in two forms a T (tense) inactive state and R (relaxed) state. Phosphorylase b is normally in the T state, inactive due to the physiological presence of ATP and Glucose 6 phosphate, and Phosphorylase a is normally in the R  state (active).
The hepatic '''glycogen phosphorylase a''' (the active form of the enzyme by phosphorylation) a is converted from [[Allosteric regulation|relax]] form to the [[Allosteric regulation|tense]] form to relaxed form if the allosteric inhibitor is present. The significance of the regulation is to salvage the glycogen when the glucose is in high level.


===Muscle===
An isoenzyme of glycogen phosphorylase exists in the liver sensitive to glucose concentration, as the liver acts as a glucose exporter. In essence, liver phosphorylase is responsive to glucose, which causes a very responsive transition from the R to T form, inactivating it; furthermore, liver phosphorylase is insensitive to AMP.
The '''glycogen phosphorylase b''' (the inactive form of the enzyme due to dephosphorylation)  is converted from relax form to tense form if the allosteric inhibitor, [[adenosine triphosphate|ATP]] and [[glucose-6-phosphate]] is present. The significance of the regulation is to salvage the glycogen when the energy status is high and the glucose supply to the muscle cells is high.


When AMP is concentrated, the glycogen phosphorylase b in tense conformation is converted to the relaxed form. It is to increase the glucose-6-phosphate supply for increasing the rate of glycolysis and thus the rate of ATP formation.
==Historical significance==
Glycogen phosphorylase was the first allosteric enzyme to be discovered.<ref name="PMID2137445" /> This accomplishment was one of many landmark achievements made by [[Carl Cori|Carl]] and [[Gerty Cori]].  In 1943, with the help of Arda Green, the pair illustrated that glycogen phosphorylase existed in either the {{not a typo|a}} or b forms depending on its phosphorylation state, as well as in the R or T states based on the presences of AMP.<ref name="Cori">{{cite journal |vauthors=Cori GT, Green AA | title = Crystalline muscle phosphorylase II prosthetic group | journal = Journal of Biological Chemistry | volume = 151 | issue = 1 | pages = 21–29 |date=July 1943 | pmid = | doi = | url = http://www.jbc.org/content/151/1.toc | issn = }}</ref>


==See also==
==See also==
* [[McArdle's Disease]]
 
* [[Glycogenolysis]]
 
==References==
{{Reflist}}
 
==Further reading==
{{refbegin}}
* {{cite book |author1=Voet, Judith G. |author2=Voet, Donald | title = Biochemistry | edition = 2nd | language = | publisher = J. Wiley & Sons | location = New York | year = 1995 | origyear = | pages = | chapter = Chapter 17: Glycogen Metabolism | quote = | isbn = 0-471-58651-X | oclc = | doi = | url = | accessdate = }}
* {{cite book |author1=Voet, Judith G. |author2=Voet, Donald | title = Biochemistry | edition = 3rd | language = | publisher = J. Wiley & Sons | location = New York | year = 2004 | origyear = | pages =  | chapter = Chapter 18: Glycogen Metabolism | quote = | isbn = 0-471-19350-X | oclc = | doi = | url = | accessdate = }}
{{refend}}


==External links==
==External links==
*  [https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=gsd6  GeneReviews/NCBI/NIH/UW entry on Glycogen Storage Disease Type VI - Hers disease]
* {{MeshName|Glycogen+phosphorylase}}
* {{MeshName|Glycogen+phosphorylase}}
* {{cite web | url = http://rpi.edu/dept/bcbp/molbiochem/MBWeb/mb1/part2/glycogen.htm#animat1 | title = Glycogen Metabolism | author = Diwan JJ | date = | format = | work = Molecular Biochemistry I | publisher = Rensselaer Polytechnic Institute | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = 2009-01-10}}
* {{cite web | url = http://www.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb24_1.html | title = Glycogen Phosphorylase | author = Goodsell  DS | date = 2001-12-01 | work = Molecule of the Month | publisher = RCSB Protein Data Bank | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = 2009-01-10}}


[[Category:EC 2.4.1]]
{{Glycogenolysis}}
{{Glycogenolysis}}
{{Glycosyltransferases}}
{{Glycosyltransferases}}
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}


[[de:Glycogenphosphorylase]]
{{DEFAULTSORT:Glycogen Phosphorylase}}
[[fr:Glycogène phosphorylase]]
[[Category:EC 2.4.1]]
[[it:Fosforilasi]]
[[pl:Fosforylaza glikogenu]]
 
{{WH}}
{{WikiDoc Sources}}
{{jb1}}

Revision as of 06:09, 24 November 2017

Phosphorylase
File:GlycogenPhosphorylaseDimer.png
The crystal structure of the rabbit muscle glycogen phosphorylase-AMP complex. AMP allosteric site (yellow), phosphorylated Ser14 (orange), glycogen binding site (blue), catalytic site (red).[1]
Identifiers
EC number2.4.1.1
CAS number9035-74-9
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO

Glycogen phosphorylase is one of the phosphorylase enzymes (EC 2.4.1.1). Glycogen phosphorylase catalyzes the rate-limiting step in glycogenolysis in animals by releasing glucose-1-phosphate from the terminal alpha-1,4-glycosidic bond. Glycogen phosphorylase is also studied as a model protein regulated by both reversible phosphorylation and allosteric effects.

Mechanism

Glycogen phosphorylase breaks up glycogen into glucose subunits (see also figure below):

(α-1,4 glycogen chain)n + Pi ⇌ (α-1,4 glycogen chain)n-1 + α-D-glucose-1-phosphate.[2]

Glycogen is left with one fewer glucose molecule, and the free glucose molecule is in the form of glucose-1-phosphate. In order to be used for metabolism, it must be converted to glucose-6-phosphate by the enzyme phosphoglucomutase.

Although the reaction is reversible in solution, within the cell the enzyme only works in the forward direction as shown below because the concentration of inorganic phosphate is much higher than that of glucose-1-phosphate.[2]

Action of Glycogen Phosphorylase on Glycogen
Action of Glycogen Phosphorylase on Glycogen

Glycogen phosphorylase can act only on linear chains of glycogen (α1-4 glycosidic linkage). Its work will immediately come to a halt four residues away from α1-6 branch (which are exceedingly common in glycogen). In these situations, a debranching enzyme is necessary, which will straighten out the chain in that area. In addition, the enzyme transferase shifts a block of 3 glucosyl residues from the outer branch to the other end, and then a α1-6 glucosidase enzyme is required to break the remaining (single glucose) α1-6 residue that remains in the new linear chain. After all this is done, glycogen phosphorylase can continue. The enzyme is specific to α1-4 chains, as the molecule contains a 30-angstrom-long crevice with the same radius as the helix formed by the glycogen chain; this accommodates 4-5 glucosyl residues, but is too narrow for branches. This crevice connects the glycogen storage site to the active, catalytic site.

Glycogen phosphorylase has a pyridoxal phosphate (PLP, derived from Vitamin B6) at each catalytic site. Pyridoxal phosphate links with basic residues (in this case Lys680) and covalently forms a Schiff base. Once the Schiff base linkage is formed, holding the PLP molecule in the active site, the phosphate group on the PLP readily donates a proton to an inorganic phosphate molecule, allowing the inorganic phosphate to in turn be deprotonated by the oxygen forming the α-1,4 glycosidic linkage. PLP is readily deprotonated because its negative charge is not only stabilized within the phosphate group, but also in the pyridine ring, thus the conjugate base resulting from the deprotonation of PLP is quite stable. The protonated oxygen now represents a good leaving group, and the glycogen chain is separated from the terminal glycogen in an SN1 fashion, resulting in the formation of a glucose molecule with a secondary carbocation at the 1 position. Finally, the deprotonated inorganic phosphate acts as a nucleophile and bonds with the carbocation, resulting in the formation of glucose-1-phosphate and a glycogen chain shortened by one glucose molecule.

There is also an alternative proposed mechanism involving a positively charged oxygen in a half-chair conformation.[3]

Catalytic Site Mechanism
Catalytic Site Mechanism

Structure

The glycogen phosphorylase monomer is a large protein, composed of 842 amino acids with a mass of 97.434 kDa in muscle cells. While the enzyme can exist as an inactive monomer or tetramer, it is biologically active as a dimer of two identical subunits.[4]

File:GlycogenPhosphorylaseTandRStates.png
R and T States of Glycogen Phosphorylase b Tower Helices, on the left and right respectively. Note the relative positioning of the central tower helices, as well as the increased interactions between subunits in the R state. PDB3CEH, PDB3E3O

In mammals, the major isozymes of glycogen phosphorylase are found in muscle, liver, and brain. The brain type is predominant in adult brain and embryonic tissues, whereas the liver and muscle types are predominant in adult liver and skeletal muscle, respectively.[5]

The glycogen phosphorylase dimer has many regions of biological significance, including catalytic sites, glycogen binding sites, allosteric sites, and a reversibly phosphorylated serine residue. First, the catalytic sites are relatively buried, 15Å from the surface of the protein and from the subunit interface.[6] This lack of easy access of the catalytic site to the surface is significant in that it makes the protein activity highly susceptible to regulation, as small allosteric effects could greatly increase the relative access of glycogen to the site.

Perhaps the most important regulatory site is Ser14, the site of reversible phosphorylation very close to the subunit interface. The structural change associated with phosphorylation, and with the conversion of phosphorylase b to phosphorylase a, is the arrangement of the originally disordered residues 10 to 22 into α helices. This change increases phosphorylase activity up to 25% even in the absence of AMP, and enhances AMP activation further.[7]

The allosteric site of AMP binding on muscle isoforms of glycogen phosphorylase are close to the subunit interface just like Ser14. Binding of AMP at this site, corresponding in a change from the T state of the enzyme to the R state, results in small changes in tertiary structure at the subunit interface leading to large changes in quaternary structure.[8] AMP binding rotates the tower helices (residues 262-278) of the two subunits 50˚ relative to one another through greater organization and intersubunit interactions. This rotation of the tower helices leads to a rotation of the two subunits by 10˚ relative to one another, and more importantly disorders residues 282-286 (the 280s loop) that block access to the catalytic site in the T state but do not in the R state.[6]

The final, perhaps most curious site on the glycogen phosphorylase protein is the so-called glycogen storage site. Residues 397-437 form this structure, which allows the protein to covalently bind to the glycogen chain a full 30 Å from the catalytic site . This site is most likely the site at which the enzyme binds to glycogen granules before initiating cleavage of terminal glucose molecules. In fact, 70% of dimeric phosphorylase in the cell exists as bound to glycogen granules rather than free floating.[9]

Clinical significance

phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V)
Identifiers
SymbolPYGM
Entrez5837
HUGO9726
OMIM608455
RefSeqNM_005609
UniProtP11217
Other data
EC number2.4.1.1
LocusChr. 11 q12-q13.2
phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)
Identifiers
SymbolPYGL
Entrez5836
HUGO9725
OMIM232700
RefSeqNM_002863
UniProtP06737
Other data
EC number2.4.1.1
LocusChr. 14 q11.2-24.3
phosphorylase, glycogen; brain
Identifiers
SymbolPYGB
Entrez5834
HUGO9723
OMIM138550
RefSeqNM_002862
UniProtP11216
Other data
EC number2.4.1.1
LocusChr. 20 p11.2-p11.1

The inhibition of glycogen phosphorylase has been proposed as one method for treating type 2 diabetes.[10] Since glucose production in the liver has been shown to increase in type 2 diabetes patients,[11] inhibiting the release of glucose from the liver’s glycogen’s supplies appears to be a valid approach. The cloning of the human liver glycogen phosphorylase (HLGP) revealed a new allosteric binding site near the subunit interface that is not present in the rabbit muscle glycogen phosphorylase (RMGP) normally used in studies. This site was not sensitive to the same inhibitors as those at the AMP allosteric site,[12] and most success has been had synthesizing new inhibitors that mimic the structure of glucose, since glucose-6-phosphate is a known inhibitor of HLGP and stabilizes the less active T-state.[13] These glucose derivatives have had some success in inhibiting HLGP, with predicted Ki values as low as 0.016 mM.[14]

Mutations in the muscle isoform of glycogen phosphorylase (PYGM) are associated with glycogen storage disease type V (GSD IV, McArdle's Disease). More than 65 mutations in the PYGM gene that lead to McArdle disease have been identified to date.[15][16] Symptoms of McArdle disease include muscle weakness, myalgia, and lack of endurance, all stemming from low glucose levels in muscle tissue.[17]

Mutations in the liver isoform of glycogen phosphorylase (PYGL) are associated with Hers' Disease (glycogen storage disease type VI).[18][19] Hers' disease is often associated with mild symptoms normally limited to hypoglycemia, and is sometimes difficult to diagnose due to residual enzyme activity.[20]

The brain isoform of glycogen phosphorylase (PYGB) has been proposed as a biomarker for gastric cancer.[21]

Regulation

Glycogen phosphorylase is regulated by both allosteric control and by phosphorylation.

Hormones such as epinephrine, insulin and glucagon regulate glycogen phosphorylase using second messenger amplification systems that are linked to G proteins. Glucagon activates adenylate cyclase through a seven transmembrane receptor coupled to Gs which, in turn, activates adenylate cyclase to increase intracellular concentrations of cAMP. cAMP binds to and releases an active form of protein kinase A (PKA). Next, PKA phosphorylates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase b, transforming it into the active glycogen phosphorylase a. This phosphorylation is added onto the glycogen phosphorylase b serine 14. In the liver, glucagon activates another G-protein-linked receptor that triggers a different cascade, resulting in the activation of Phospholipase C (PLC). PLC indirectly causes the release of calcium from the hepatocytes' endoplasmic reticulum into the cytosol. The increased calcium availability binds to the calmodulin subunit and activates glycogen phosphorylase kinase. Glycogen phosphorylase kinase activates glycogen phosphorylase in the same manner mentioned previously.

Glycogen phosphorylase b is not always inactive in muscle, as it can be activated allosterically by AMP. An increase in AMP concentration, which occurs during strenuous exercise, signals energy demand. AMP activates glycogen phosphorylase b by changing its conformation from a tense to a relaxed form. This relaxed form has similar enzymatic properties as the phosphorylated enzyme. An increase in ATP concentration opposes this activation by displacing AMP from the nucleotide binding site, indicating sufficient energy stores.

Upon eating a meal, there is a release of insulin, signaling glucose availability in the blood. Insulin indirectly activates PP-1 and phosphodiesterase. The PP-1 directly dephosphorylates glycogen phosphorylase a, reforming the inactive glycogen phosphorylase b. The phosphodiesterase converts cAMP to AMP. This activity removes the second messenger (generated by glucagon and epinephrine) and inhibits PKA. In this manner, PKA can no longer cause the phosphorylation cascade that ends with formation of (active) glycogen phosphorylase a. These modifications initiated by insulin end glycogenolysis in order to preserve what glycogen stores are left in the cell and trigger glycogenesis (rebuilding of glycogen).[22]

Phosphorylase a and phosphorylase b each exist in two forms a T (tense) inactive state and R (relaxed) state. Phosphorylase b is normally in the T state, inactive due to the physiological presence of ATP and Glucose 6 phosphate, and Phosphorylase a is normally in the R state (active).

An isoenzyme of glycogen phosphorylase exists in the liver sensitive to glucose concentration, as the liver acts as a glucose exporter. In essence, liver phosphorylase is responsive to glucose, which causes a very responsive transition from the R to T form, inactivating it; furthermore, liver phosphorylase is insensitive to AMP.

Historical significance

Glycogen phosphorylase was the first allosteric enzyme to be discovered.[8] This accomplishment was one of many landmark achievements made by Carl and Gerty Cori. In 1943, with the help of Arda Green, the pair illustrated that glycogen phosphorylase existed in either the a or b forms depending on its phosphorylation state, as well as in the R or T states based on the presences of AMP.[23]

See also

References

  1. ↑ PDB: 3E3N​
  2. ↑ 2.0 2.1 Livanova NB, Chebotareva NA, Eronina TB, Kurganov BI (May 2002). "Pyridoxal 5′_Phosphate as a Catalytic and Conformational Cofactor of Muscle Glycogen Phosphorylase b". Biochemistry (Moscow). 67 (10): 1089–1998. doi:10.1023/A:1020978825802. PMID 12460107.
  3. ↑ Palm D, Klein HW, Schinzel R, Buehner M, Helmreich, EJ (February 1990). "The role of pyridoxal 5'-phosphate in glycogen phosphorylase catalysis". Biochemistry. 29 (5): 1099–1107. doi:10.1021/bi00457a001. PMID 2182117.
  4. ↑ Browner MF, Fletterick RJ (February 1992). "Phosphorylase: a biological transducer". Trends in Biochemical Sciences. 17 (2): 66–71. doi:10.1016/0968-0004(92)90504-3. PMID 1566331.
  5. ↑ David ES, Crerar MM (January 1986). "Quantitation of muscle glycogen phosphorylase mRNA and enzyme amounts in adult rat tissues". Biochim. Biophys. Acta. 880 (1): 78–90. doi:10.1016/0304-4165(86)90122-4. PMID 3510670.
  6. ↑ 6.0 6.1 Johnson LN (March 1992). "Glycogen phosphorylase: control by phosphorylation and allosteric effectors". FASEB Journal. 6 (6): 2274–82. PMID 1544539.
  7. ↑ Newgard CB, Hwang PK, Fletterick RJ (1989). "The family of glycogen phosphorylases: structure and function". Critical Reviews Biochemistry and Molecular Biology. 24 (1): 69–99. doi:10.3109/10409238909082552. PMID 2667896.
  8. ↑ 8.0 8.1 Johnson LN, Barford D (February 1990). "Glycogen phosphorylase. The structural basis of the allosteric response and comparison with other allosteric proteins". Journal of Biological Chemistry. 265 (5): 2409–2412. PMID 2137445.
  9. ↑ Meyer F, Heilmeyer LM Jr, Haschke RH, Fischer EH (Dec 1970). "Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein-glycogen complex". Journal of Biological Chemistry. 245 (24): 6642–6648. PMID 4320610.
  10. ↑ Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P (2003). "Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments". Current Pharmacological Design. 9 (15): 1177–89. doi:10.2174/1381612033454919. PMID 12769745.
  11. ↑ Moller DE (Dec 2001). "New drug targets for type 2 diabetes and the metabolic syndrome". Nature. 414 (6865): 821–7. doi:10.1038/414821a. PMID 11742415.
  12. ↑ Coats WS, Browner MF, Fletterick RJ, Newgard CB (Aug 1991). "An engineered liver glycogen phosphorylase with AMP allosteric activation". Journal of Biological Chemistry. 266 (24): 16113–9. PMID 1874749.
  13. ↑ Oikonomakos NG, Kontou M, Zographos SE, Tsitoura HS, Johnson LN, Watson KA, Mitchell EP, Fleet GW, Son JC, Bichard CJ, et al. (Jul 1994). "The design of potential antidiabetic drugs: experimental investigation of a number of beta-D-glucose analogue inhibitors of glycogen phosphorylase". European Journal of Drug Metabolism and Pharmacology. 19 (3): 185–92. doi:10.1007/BF03188920. PMID 7867660.
  14. ↑ Hopfinger AJ, Reaka A, Venkatarangan P, Duca JS, Wang S (Sep 1999). "Prediction of Ligand−Receptor Binding Free Energy by 4D-QSAR Analysis: Application to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase". Journal of Chemical Information and Computer Science. 39: 1141–1150. doi:10.1021/ci9900332.
  15. ↑ Nogales-Gadea G, Arenas J, Andreu AL (January 2007). "Molecular genetics of McArdle's disease". Curr Neurol Neurosci Rep. 7 (1): 84–92. doi:10.1007/s11910-007-0026-2. PMID 17217859.
  16. ↑ Andreu AL, Nogales-Gadea G, Cassandrini D, Arenas J, Bruno C (July 2007). "McArdle disease: molecular genetic update". Acta Myol. 26 (1): 53–7. PMC 2949323. PMID 17915571.
  17. ↑ Grünfeld JP, Ganeval D, Chanard J, Fardeau M, Dreyfus JC (Jun 1972). "Acute renal failure in McArdle's disease. Report of two cases". New England Journal of Medicine. 286 (23): 1237–41. doi:10.1056/NEJM197206082862304. PMID 4502558.
  18. ↑ Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW (April 1998). "Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI". Am. J. Hum. Genet. 62 (4): 785–91. doi:10.1086/301790. PMC 1377030. PMID 9529348.
  19. ↑ Chang S, Rosenberg MJ, Morton H, Francomano CA, Biesecker LG (May 1998). "Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI". Hum. Mol. Genet. 7 (5): 865–70. doi:10.1093/hmg/7.5.865. PMID 9536091.
  20. ↑ Tang NL, Hui J, Young E, Worthington V, To KF, Cheung KL, Li CK, Fok TF (Jun 2003). "A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity". Molecular Genetics and Metabolism. 79 (2): 142–145. doi:10.1016/S1096-7192(03)00068-4. PMID 12809646.
  21. ↑ Shimada S, Matsuzaki H, Marutsuka T, Shiomori K, Ogawa M (July 2001). "Gastric and intestinal phenotypes of gastric carcinoma with reference to expression of brain (fetal)-type glycogen phosphorylase". J. Gastroenterol. 36 (7): 457–64. doi:10.1007/s005350170068. PMID 11480789.
  22. ↑ Alemany, Susana; Pelech, Steven; Brierley, Cathy H.; Cohen, Philip (1986-04-01). "The protein phosphatases involved in cellular regulation". European Journal of Biochemistry. 156 (1): 101–110. doi:10.1111/j.1432-1033.1986.tb09554.x. ISSN 1432-1033.
  23. ↑ Cori GT, Green AA (July 1943). "Crystalline muscle phosphorylase II prosthetic group". Journal of Biological Chemistry. 151 (1): 21–29.

Further reading

  • Voet, Judith G.; Voet, Donald (1995). "Chapter 17: Glycogen Metabolism". Biochemistry (2nd ed.). New York: J. Wiley & Sons. ISBN 0-471-58651-X.
  • Voet, Judith G.; Voet, Donald (2004). "Chapter 18: Glycogen Metabolism". Biochemistry (3rd ed.). New York: J. Wiley & Sons. ISBN 0-471-19350-X.

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Glycogen_phosphorylase&oldid=1414668"